UK molecular-diagnostics firm DNA Electronics presented data supporting its LiDia-SEQ rapid sequencing platform and announced plans to commercialize the cartridge-based instrument in 2027. Company posters at the Association for Molecular Pathology meeting showed same-day detection of bloodstream pathogens and antibiotic resistance markers directly from whole blood using a prototype. DNAe’s LiDia-SEQ uses semiconductor sequencing derived from Ion Torrent technology combined with proprietary sample prep, clonal amplification and local basecalling to deliver automated, sample-to-report results. CEO Sam Reed said the first clinical application will target sepsis diagnostics to enable targeted antibiotic therapy within hours rather than days.